Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 27, 2016 16:00 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Announces Board Changes

PHILADELPHIA and OXFORD, United Kingdom, Oct. 27, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP) (“Adaptimmune” or the “Company”), a leader in T-cell therapy to treat cancer,...
October 27, 2016 10:05 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Announces Collaboration with MSD to Evaluate KEYTRUDA® (pembrolizumab) in Combination with NY-ESO SPEAR® T-Cell Therapy in Multiple Myeloma

PHILADELPHIA and OXFORD, United Kingdom, Oct. 27, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has...
October 18, 2016 08:00 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Announces Initiation of Triple Tumor Study to Evaluate its SPEAR® T-Cell Therapy Targeting MAGE-A10

PHILADELPHIA and OXFORD, United Kingdom, Oct. 18, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has...
October 12, 2016 09:15 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Provides Update on Clinical Study Evaluating its SPEAR® T-Cell Therapy Targeting NY-ESO-1 in Ovarian Cancer

PHILADELPHIA and OXFORD, United Kingdom, Oct. 12, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that its amended...
October 09, 2016 10:00 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Provides Update on Study of NY-ESO SPEAR® T-cell Therapy in Synovial Sarcoma at the European Society for Medical Oncology (ESMO) 2016 Congress

PHILADELPHIA and OXFORD, United Kingdom, Oct. 09, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced a poster...
October 05, 2016 16:30 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune to Provide Update on Study of NY-ESO SPEAR® T-cell Therapy in Synovial Sarcoma at the European Society for Medical Oncology (ESMO) 2016 Congress

PHILADELPHIA and OXFORD, United Kingdom, Oct. 05, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, announced that it will present a...
September 26, 2016 07:30 ET | Source: Adaptimmune Therapeutics plc

MD Anderson Cancer Center and Adaptimmune Form Strategic Alliance to Advance Development of Immunotherapies Targeting Multiple Cancers

PHILADELPHIA and HOUSTON, United States and OXFORD, United Kingdom, Sept. 26, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, and...
September 19, 2016 07:30 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Announces Strategic Manufacturing Agreement with PCT to Support Development of SPEAR® T-cell Therapies Towards Commercialization

PHILADELPHIA and OXFORD, United Kingdom, Sept. 19, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has...
September 08, 2016 14:45 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune to Participate in Two Upcoming Investor Conferences

PHILADELPHIA, and OXFORD, United Kingdom, Sept. 08, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today...
August 08, 2016 07:00 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Reports Second Quarter 2016 Financial Results

- Conference call to be held today at 8:00 AM ET (1:00 PM BST) - PHILADELPHIA and OXFORD, United Kingdom, Aug. 08, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP)...